Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Guselkumab Meets Primary, Key Secondary Endpoints in Phase 4 STAR Study of Axial PsA

26 September 2026 · By · Wire by Fusion42

Published

26 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at thedermdigest.com →

◆ Verified

Fusion42 · 27 September 2026 · Fusion42 review

Guselkumab met primary and key secondary endpoints in the Phase 4 STAR study, showing improvement in axial symptoms and reduction in MRI-confirmed inflammation for biologic-naïve adults with axial psoriatic arthritis.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You face a new standard of evidence for psoriasis arthritis treatments that includes objective MRI endpoints alongside patient symptoms. This trial's design opens the door to more rigorous product differentiation through imaging biomarkers.

◆ Coverage

1 source · 26 Sep 2026

◆ Related on Wire

◆ Topics

Biotechpsoriatic-arthritisguselkumabphase-4clinical-trialbio-naive